Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three‐way crossover study
- 30 March 2006
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 23 (8) , 1179-1187
- https://doi.org/10.1111/j.1365-2036.2006.02781.x
Abstract
The effectiveness of proton pump inhibitors is influenced by meals and administration time. To compare the effects on intragastric acidity of times of dosing of tenatoprazole, a novel imidazopyridine-based proton pump inhibitor with a prolonged plasma half-life. This randomized three-period crossover study included 12 Helicobacter pylori-negative healthy subjects, who received tenatoprazole 40 mg either fasting at 7.00 AM, fasting at 7.00 PM or fed at 9.30 PM for 7 days, with a 2-week washout between periods. Twenty-four hour intragastric pH was monitored on day 7 of each period. On day 7, median 24-h pH was 4.7, 5.1 and 4.7 after breakfast, dinner and bedtime dosing, respectively (P = 0.11), whereas night-time pH was 4.2, 5.0 and 4.4 (P = 0.13). The mean 24-h percentage of time over pH 4 was 62, 72 and 64 after breakfast, dinner and bedtime dosing, respectively (N.S.), and 54, 68 and 56 during night-time (P = 0.06). Nocturnal acid breakthrough incidence decreased from 100% at baseline to 83%, 55% and 75% after 7.00 AM, 7.00 PM and 9.30 PM dosing, respectively (P = 0.18), and its mean duration dropped from 6.2 to 2.8, 1.0 and 2.2 h, respectively (P < 0.05). Seven-day administration of tenatoprazole provides a prolonged duration of acid suppression, especially during the night-time, with little effect of food or time of dosing.Keywords
This publication has 23 references indexed in Scilit:
- A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteersAlimentary Pharmacology & Therapeutics, 2005
- Intragastric acid suppression and pharmacokinetics of twice‐daily esomeprazole: a randomized, three‐way crossover studyAlimentary Pharmacology & Therapeutics, 2004
- Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthroughAlimentary Pharmacology & Therapeutics, 2004
- Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half‐life: effects on intragastric pH and comparison with esomeprazole in healthy volunteersAlimentary Pharmacology & Therapeutics, 2004
- An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapyAlimentary Pharmacology & Therapeutics, 2002
- Gastric acidity and acid breakthrough with twice‐daily omeprazole or lansoprazoleAlimentary Pharmacology & Therapeutics, 2000
- General pharmacological properties of the new proton pump inhibitor (+/-)-5-methoxy-2-(((methoxy-3,5-dimethylpyrid-2-yl)methyl)sulfinyl)-1H-imidazo(4,5-b)pyridineMethods and Findings in Experimental and Clinical Pharmacology, 1999
- Gastro‐oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitorsAlimentary Pharmacology & Therapeutics, 1998
- Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis.Gut, 1996
- Omeprazole (20 mg) daily given in the morning or evening: a comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentrationAlimentary Pharmacology & Therapeutics, 1992